In this, the second part of a two part series, Brendan Weiss, MD, offers an interrogative on the diagnosis and treatment of AL amyloidosis, a disorder associated with plasma cell dyscrasia. Dr. Weiss considers the current potential for early diagnosis of the disease, and the potential for highly active antiplasma cell chemotherapy regimens (and other therapies) to improve outcomes in advanced cardiac amyloidosis.
Related Links
Published
June 3, 2015
Created by
BROADCASTMED